PAT5A: A Partial Agonist of Peroxisome Proliferator-Activated Receptor γ Is a Potent Antidiabetic Thiazolidinedione Yet Weakly Adipogenic
- 2 May 2003
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Journal of Pharmacology and Experimental Therapeutics
- Vol. 306 (2), 763-771
- https://doi.org/10.1124/jpet.103.049791
Abstract
PAT5A [5-[4-[N-(2-pyridyl)-(2S)-pyrrolidine-2-methoxyl]phenylmethylene[thiazolidine-2,4-dione, malic acid salt]], a chemically distinct unsaturated thiazolidinedione, activates peroxisome proliferator-activated receptor γ (PPARγ) submaximally in vitro with the binding affinity ∼10 times less than that of rosiglitazone, a highly potent thiazolidinedione. PAT5A reduces plasma glucose level and improves insulin sensitivity in insulin resistant db/db mice, similar to that of rosiglitazone, while exerting a relatively weak adipogenic effect. In contrast to rosiglitazone, PAT5A inhibits cholesterol and fatty acid biosynthesis suggesting that PAT5A possesses a unique receptor-independent non-PPAR related property. PAT5A induces qualitatively similar but quantitatively different protease digestion patterns and interacts with PPARγ differently than rosiglitazone. PAT5A shows differential cofactor recruitment and gene activation than that of rosiglitazone. Thus, the partial agonism of PAT5A to PPARγ together with its receptor independent effects may contribute to its antidiabetic potency similar to rosiglitazone in vivo despite reduced affinity for PPARγ. These biological effects suggest that PAT5A is a PPARγ modulator that activates some (insulin sensitization), but not all (adipogenesis), PPARγ-signaling pathways.Keywords
This publication has 25 references indexed in Scilit:
- Interaction of PIMT with Transcriptional Coactivators CBP, p300, and PBP Differential Role in Transcriptional RegulationPublished by Elsevier ,2002
- Signal Transduction and the Control of Gene ExpressionScience, 2002
- Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone.Diabetes, 2000
- Peroxisome Proliferator-Activated Receptors: Nuclear Control of MetabolismEndocrine Reviews, 1999
- Nuclear Receptor Coregulators: Cellular and Molecular BiologyEndocrine Reviews, 1999
- Molecular basis of agonism and antagonism in the oestrogen receptorNature, 1997
- Time-efficient flexible superposition of medium-sized moleculesJournal of Computer-Aided Molecular Design, 1997
- Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db miceEndocrinology, 1996
- The nuclear receptor superfamily: The second decadeCell, 1995
- Purification and characterization of the isozymes of phosphoenolpyruvate carboxykinase from rabbit liverBiochimica et Biophysica Acta (BBA) - General Subjects, 1988